BioSante Pharmaceuticals first-one fourth net loss raises to $10.5 million BioSante Pharmaceuticals, Inc tadalafil from india http://tadalafilmed.com . today reported on its latest developments and financial outcomes for the first one fourth, and its own cash balance by March 31, 2010. Latest BioSante Developments Closed $18 million Registered Immediate Financing: BioSante added around $18 million to its cash balance due to its March 2010 authorized direct offering, getting its March 31, 2010 cash stability to around $41.2 million. The LibiGel safety research continues, with no adjustments, based on the wonderful basic safety profile observed to day.
To learn more, visit.. . The 10-calendar year exclusive distribution rights contract is component of an expansion of the making and supply agreement between your companies for immunodiagnostic screening for bloodstream virus and infectious disease, which began twenty years ago nearly. develops, manufactures, and marketplaces a broad selection of innovative items and solutions for the life span science research and medical diagnostic markets. The business is renowned because of its dedication to quality and customer support among university and analysis institutions, hospitals, public health insurance and commercial laboratories, along with the biotechnology, pharmaceutical, and meals safety sectors.